Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis by Sebastiani, M. et al.
S-221Clinical and Experimental Rheumatology 2020
1Rheumatology Unit, University of 
Modena and Reggio Emilia, Azienda 
Ospedaliero-Universitaria Policlinico 
di Modena, Modena; 
2PhD program in Clinical and 
Experimental Medicine, University of 
Modena and Reggio Emilia; 
3Rheumatology Unit, Santa Maria 
Hospital, IRCCS, Reggio Emilia; 
4Department of Medicine and Surgery, 
University of Milan Bicocca, Respiratory 
Unit, San Gerardo Hospital, ASST Monza; 
5Pathology Unit, AUSL/IRCCS, Reggio 
Emilia; 6Section of Radiology, Unit of 
Surgical Sciences, Department of Medicine
 and Surgery (DiMeC), University of 
Parma, Italy.
Marco Sebastiani, MD
Andreina Manfredi, MD
Caterina Vacchi, PhD
Giulia Cassone, PhD
Paola Faverio, MD
Alberto Cavazza, MD
Nicola Sverzellati, Prof
Carlo Salvarani, Prof
Fabrizio Luppi, Prof
Please address correspondence to:
Marco Sebastiani
Dipartimento di Reumatologia, 
Università degli Studi di Modena 
e Reggio Emilia, 
Via del Pozzo, 71, 
41121 Modena, Italy.
E-mail: marco.sebastiani@unimore.it
Received on March 8, 2020; accepted in 
revised form on April 16, 2020.
Clin Exp Rheumatol 2020; 38 (Suppl. 124): 
S221-S231.
© Copyright CLINICAL AND 
EXPERIMENTAL RHEUMATOLOGY 2020.
Key words: interstitial lung disease, 
ANCA-associated vasculitis, 
microscopic polyangiitis, alveolar 
haemorrhage, usual interstitial 
pneumonia
Competing interests: none declared.
ABSTRACT
Antineutrophil cytoplasmic antibodies 
(ANCA)-associated vasculitis (AAV) is 
a group of systemic vasculitides that 
predominantly affect small vessels, in-
cluding granulomatosis with polyangii-
tis (GPA), microscopic polyangiitis 
(MPA), and eosinophilic granulomato-
sis with polyangiitis (EGPA).
Pulmonary involvement is frequently 
observed in AAV patients, with various 
possible phenotypes in the different dis-
eases. In the last years, among the pos-
sible types of lung involvement, a grow-
ing interest has been addressed to the 
interstitial lung disease (ILD). 
Prevalence of ILD is higher in MPA 
than in GPA; in fact, ILD has been re-
ported in up to 45% of MPA patients 
and in 23% of GPA. Anti-MPO antibod-
ies are the main ANCA subtype associ-
ated to ILD, in about 46-71% of cases, 
while anti-PR3 antibodies are reported 
in 0-29% of patients.
High resolution computed tomography 
(HRCT) frequently detects interstitial 
lung abnormalities in AAV, up to 66% 
of patients with MPA, even if with an 
XQFOHDU FOLQLFDO UHOHYDQFH VSHFLÀFDOO\
in asymptomatic patients. Ground glass 
opacities, mainly consistent with diffuse 
alveolar haemorrhage (DAH), are the 
PRVW IUHTXHQWÀQGLQJLQ03$SDWLHQWV
but reticulations, interlobular septal 
thickening and honeycombing are also 
reported.
,/'VLJQLÀFDQWO\DIIHFWVTXDOLW\RI OLIH
and survival, with mortality increased 
2 to 4 times, particularly higher in MPA 
SDWLHQWVZLWKSXOPRQDU\ÀEURVLV
Currently, immunosuppressive therapy 
is considered also as a possible treat-
ment of ILD. However, a careful evalu-
ation of progression and severity of 
lung involvement, should guide the 
treatment decision in the single patient.
In this review, we discuss the available 
evidence on clinical features, diagnos-
tic work-up, prognosis and manage-
ment of AAV-ILD. 
ANCA-associated vasculitis: 
LQWURGXFWLRQDQGFODVVLÀFDWLRQ
criteria
Antineutrophil cytoplasmic antibodies 
(ANCA)-associated vasculitis (AAV) 
is a heterogeneous group of systemic 
vasculitides that predominantly affect 
small vessels, including granulomatosis 
with polyangiitis (GPA), microscop-
ic polyangiitis (MPA), together with 
renal-limited vasculitis, and eosino-
philic granulomatosis with polyangiitis 
(EGPA) (1). AAV is associated with 
myeloperoxidase (MPO) or proteinase 
3 (PR3) ANCA. However, cases of AN-
CA-negative AAV can occur, especially 
in EGPA but also in GPA (2). Although 
PDQ\ FODVVLÀFDWLRQ FULWHULD DUH DYDLO-
able for AAV, a differential diagnosis 
between GPA and MPA is sometimes 
unreliable, and a diagnosis of unclassi-
ÀHGIRUPLVRFFDVLRQDOO\PDGH
The different types of ANCA have 
been associated to different disease 
extent and severity, with regard to re-
lapse risk, response to therapy, and pa-
tient outcome; therefore, some authors 
proposed to classify AAV on the basis 
RIWKH´DXWRDQWLERG\SURÀOHµDV´35
$1&$µ ´032$1&$µ RU ´VHURQ-
HJDWLYHµ GLVHDVH 1HYHUWKHOHVV QRQH
RIWKH$1&$VSHFLÀFLWLHVLVSDWKRJQR-
monic for any clinical feature (2, 4).
A careful clinical assessment of pa-
tients, a screening for all potentially 
affected organs and a categorisation 
of disease severity remain the best ap-
proach to predict disease prognosis and 
to tailor the treatment, considering the 
FRPSOHPHQWDU\UROHRI$1&$VSHFLÀ-
cities and clinical phenotypes (3, 5).
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Pulmonary involvement is frequently 
observed in AAV patients, and in the last 
years a growing number of evidence has 
been published on the interstitial lung 
involvement in these conditions.
In this paper, we review clinical fea-
tures, diagnostic work-up, prognosis 
and management of interstitial lung 
disease (ILD) associated to AAV. The 
role of ANCA in patients with idi-
opathic interstitial pneumonias (IIPs) 
without an AAV will be also evaluated.
Pulmonary features of 
granulomatosis with polyangiitis
GPA is a systemic vasculitis character-
ised by granulomatous lesions and ne-
crotising vasculitis with an incidence 
estimated as 4 to 21 cases/million. The 
peak incidence is in the fourth through 
seventh decades of life, without gen-
der predominance (6, 7). Although 
any organs may be affected, the up-
per and lower respiratory tract, along 
with kidney, are the most frequently 
organs involved in GPA. Moreover, 
GPA represents the most common pul-
monary vasculitis (8, 9). About 90% of 
patients affected by GPA presents het-
erogeneous pulmonary manifestations 
at high resolution computed tomogra-
phy (HRCT), including lung nodules, 
segmental bronchial wall thickening, 
septal lines, consolidations, lobar bron-
chial wall thickening, and bronchiecta-
sis (10).
Non-cavitated nodules, consolidations, 
SXOPRQDU\LQÀOWUDWHVDQGJURXQGJODVV
opacities (GGO) are usually consid-
ered as features of mild parenchymal 
disease, while other lung complica-
tions, such as alveolar haemorrhage or 
cavitated nodules can be life-threaten-
ing and require an early diagnosis and 
prompt therapeutic approach (11).
Nodules are the most frequent pulmo-
QDU\ÀQGLQJLQ*3$WKH\DUHELODWHUDO
without regional predisposition, with 
different amount of granulomatous in-
ÁDPPDWLRQ DQG QHFURWLF WLVVXH DW KLV-
tology. Nodules usually show a good 
response to treatment; however, they 
can be complicated by cavitation, es-
pecially in case of nodules larger than 
2 cm with irregular margins, that can 
sometimes become infected (12). 
Bilateral irregular consolidations can 
also be detected and generally repre-
VHQWJUDQXORPDWRXVLQÁDPPDWLRQZLWK
necrosis and organising pneumonia. 
They are more frequently detected in 
wedge-shaped areas of peripheral con-
solidation abutting the pleura and mim-
icking pulmonary infarction (13). 
Alveolar haemorrhage, with or without 
capillaritis, rarely represents the clini-
cal onset of GPA, but it is recognised to 
be another cause of GGO or consolida-
tion in this type of vasculitis. Globally, 
GGO are described in about 25% of pa-
tients (6, 14).
Besides pulmonary parenchymal 
manifestations, both upper and lower 
respiratory tracts can be involved in 
the course of GPA (15, 16). airway in-
volvement is described in 95% of GPA. 
Many studies report tracheobronchial 
involvement, namely bronchial wall 
thickening, bronchiectasis of the small 
airways, but also segmental and sub-
segmental bronchial stenoses, expres-
VLRQ RI LQÁDPPDWRU\ GDPDJH 
Finally, pleural effusion is considered 
the most common pleural manifesta-
tion in GPA patients; pleuritis, pleural 
nodules, and pneumothorax have also 
been described (15) (Table I; 6, 10-18).
Pulmonary features of eosinophilic 
granulomatosis with polyangiitis
EGPA is the least common among AAV 
with an estimated incidence of 0.5 to 
6.8 cases/million (19). EGPA usually 
shows a prodromal phase, including rhi-
nosinusitis and asthma; an eosinophilic 
phase with blood and tissue eosinophil-
ia, is usually followed by the vasculitic 
phase (20). Sometimes, the different 
stages of disease overlap among them 
and are not distinguishable.
Asthma is the most common manifesta-
tion in EGPA; it can precede the onset 
of vasculitis by 3–9 years and often ful-
ÀOV WKH FULWHULD IRU VHYHUH DVWKPD 
23).
Eosinophilic pneumonia is relatively 
frequent in patients with EGPA, but 
may be underdiagnosed because of the 
mild clinical manifestations and tran-
VLHQW SXOPRQDU\ LQÀOWUDWHV UHVSRQVLYH
to corticosteroid therapy (24-26). Hy-
pereosinophilic bronchiolitis may also 
be observed, and it is characterised by 
bronchiectasis and airway abnormali-
ties, such as centrilobular nodules and 
bronchial wall thickening (27).
%RWKYDVFXODULQÁDPPDWLRQDQGHRVLQ-
RSKLOLF LQÀOWUDWLRQ FRQWULEXWH WR RUJDQ
damage, but the clinical presentation 
is heterogeneous and it is commonly 
FKDUDFWHULVHGE\QRQVSHFLÀFV\VWHPLF
symptoms, including fever, fatigue, ar-
thralgia and weight loss. Frequently, 
in patients with a previous history of 
asthma, EGPA is suspected only after 
the onset of eosinophilia and vasculitic 
manifestations (i.e. multiple monon-
euritis or purpura). Less frequently, 
asthma can be concurrent to vasculitis 
or can be absent (28). (Table II; 17-31).
Table I. Airway and pulmonary manifesta-
tions in granulomatosis with polyangiitis.
Upper airway manifestations
Sinusitis 61%
Nasal mucosa ulcers/crusting up to 70%
Saddle nose 20-50%
Nasal mass rare
Other (bone deformity)
Lower airway manifestations
Strictures and stenosis (usually 15% 
     subglottic)
Bronchiectasis 13-20%
2WKHUXOFHUVLQÁDPHGPXFRVD
Pulmonary manifestations
Cavitated and noncavitated nodules 40-89%
Consolidations 30%
Ground glass opacities 25-50%
Diffuse alveolar haemorrhage  5-10%
Pleural manifestations
Pleural nodules rare
Pneumothorax rare
Pleural effusion  12-20%
Table II. Airway and pulmonary manifes-
tations in eosinophilic granulomatosis with 
polyangiitis.
Upper airway manifestations %
 Nasal polyposis 50-76%
 Eosinophilic rhinitis 
 Chronic/recurrent rhinosinusitis 14-73%
Lower airway manifestations %
 Asthma  95-100%
 Stenosis 
 Bronchiectasis 15-20%
 Hypereosinophilic bronchiolitis  
Pulmonary manifestations %
 Eosinophilic pneumonia 38-75%
 Consolidations/Nodules 11-89%
 Ground glass opacities 39-99%
 diffuse alveolar haemorrhage  3-8%
Pulmonary manifestations %
  Pleural effusion  12-22%
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Pulmonary features of 
microscopic polyangiitis 
MPA mainly affects pulmonary and re-
nal small-size vessels, and it is charac-
WHULVHGE\QHFURWLVLQJLQÁDPPDWLRQRI
blood vessels, circulating ANCA and 
absence of necrotising parenchymal in-
ÁDPPDWLRQRQKLVWRSDWKRORJ\
The prevalence of MPA varies between 
countries, with an annual incidence es-
timated as 18.2 cases/million in Japan 
and 6.5 cases/million in Europe. The 
mean age at diagnosis is 69 years in 
Japan and 60 years in the UK, without 
gender predominance (33, 34).
Although MPA shares several clini-
cal features with GPA, systemic signs, 
such as weight loss, fever, and arthral-
gias are less frequent or mild (35). 
Moreover, differently by GPA, granu-
lomas are always lacking (8).
Diffuse alveolar haemorrhage (DAH) 
secondary to pulmonary capillaritis is 
the main lung manifestation of MPA, 
UDQJLQJ IURP LQFLGHQWDO ÀQGLQJ E\
imaging or bronchoalveolar lavage 
(BAL) to life-threatening acute respira-
tory failure (Fig. 1). 
A variable degree of DAH may rep-
resent the only lung manifestation of 
MPA in many patients, with acute or 
subacute onset; occasionally, a chronic 
occult DAH at imaging is observed, 
with siderophages found at BAL (17, 
18) (Fig. 2).
Most patients with DAH show dyspnoea 
progressing over a few days and nonspe-
FLÀF V\PSWRPV VXFK DV FRXJK DQGRU
chest pain (18). Haemoptysis is a typical 
feature when present, but it is lacking in 
about one-third of cases (36, 37).
Chest-X-ray and HRCT are usually 
QRQVSHFLÀFEXWWKHDSSHDUDQFHRIOXQJ
opacities at chest-X-ray and a reduction 
of haemoglobin or haematocrit over a 
few days are highly suggestive of DAH, 
even without haemoptysis (18).
Chest X-Ray may be normal or show 
patchy or diffuse bilateral airspace 
opacities and consolidation, usually 
widespread, sometimes prevalent in 
the peri-hilar areas and in the mid and 
lower lung zones (18, 38, 39).
GGO are the key feature at HRCT, 
without a characteristic distribution, 
and with patchy or uniform opacities. 
The presence of dense consolidations 
UHSUHVHQWV FRPSOHWH ÀOOLQJ RI WKH DO-
veoli with blood (Fig. 3) (40, 41).
'LDJQRVLVRI'$+LVXVXDOO\FRQÀUPHG
E\ %$/ ÁXLG H[DPLQDWLRQ VKRZLQJ
erythrocytes, siderophages and exclud-
ing a concomitant infection (Fig. 2). An 
increasingly haemorrhagic BAL after 
VHTXHQWLDOVDPSOLQJLVVSHFLÀFIRU'$+
and it is the best diagnostic test; when 
DAH began more than 2 days before, 
the presence of haemosiderin-laden 
alveolar macrophages (siderophages) 
Fig. 1. Acute pulmonary haemorrhage in a patient with microscopic polyangiitis, consisting in the 
LQWUDDOYHRODU DFFXPXODWLRQ RI IUHVK EORRG DQG ÀEULQZLWK D IHZ KDHPRVLGHULQÀOOHGPDFURSKDJHV
Notice the neutrophils in the alveolar septa (capillaritis). Haematoxylin-eosin, 100X. 
Fig. 2.%URQFKRDOYHRODUODYDJHÁXLGLQDSDWLHQWZLWK$1&$DVVRFLDWHGYDVFXOLWLVSUHVHQWLQJZLWK
alveolar haemorrhage, showing macrophages with coarse haemosiderin granules. Papanicolaou stain-
ing, 400X.
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FRQÀUPV WKHGLDJQRVLVRI'$+
(17); the Golde score allows to quan-
tify siderophages and a score >100 is 
pathognomonic for DAH (42). Trans-
bronchial biopsy is not mandatory for 
diagnosis, but, when performed, it 
shows a variable combination of blood, 
acute lung injury (i.e.ÀEULQRUJDQLVLQJ
pneumonia), haemosiderin deposition 
and capillaritis. Finally, surgical lung 
biopsy is no longer used for its relative 
high risk and because it rarely helps to 
ÀQGWKHFDXVHRIEOHHGLQJ
DAH should be always categorised as a 
severe complication of MPA because of 
the risk of a rapid progression to a life-
threatening condition with a high mor-
tality rate of 10% to 25% (37, 44, 45).
An oxygen saturation measured by 
pulse oximetry (SpO2) to fraction 
of inspired oxygen (FiO2) ratio of 
less than 450 at the disease onset, a 
C-reactive protein >25 mg/L, and a 
neutrophils count > 30% on the BAL 
ÁXLGKDYHEHHQLGHQWLÀHGDVLQGHSHQG-
ent risk factors for the progression to 
respiratory failure (44, 45). Therefore, 
the SpO2:FiO2 ratio should be evalu-
ated in any MPA patient presenting 
with dyspnoea or with a pulmonary in-
ÀOWUDWH HYHQ LI KDHPRSW\VLV LV DEVHQW
(45). (Table III; 17, 18, 41, 46-48).
Interstitial lung disease in 
ANCA-associated vasculitis
Epidemiology of interstitial 
lung disease in ANCA-associated 
vasculitis
In 1990 Nada et alUHSRUWHGIRUWKHÀUVW
time the presence of ILD in 2 patients 
with ANCA-associated MPA (49). 
Subsequently, in 1994, the association 
EHWZHHQ,/'DQG$$9ZDVFRQÀUPHG
by Arinuma et al. in a Japanese study, 
showing that 43% of 46 MPO-ANCA-
positive patients with connective tissue 
disease or glomerulonephritis showed 
ILD (50).
Geographic differences have also been 
described: ILD has been reported more 
frequently in Japanese cohorts with 
AAV compared to Western patients 
(46, 51-55). An increased frequency 
of alveolar haemorrhage and a higher 
prevalence of MPO-ANCA antibodies 
in Japanese patients have been pro-
posed as possible explanation for these 
differences (56-58). However, consid-
ering only MPA patients the prevalence 
of ILD seems to be similar worldwide 
(46, 51, 52).
Prevalence of ILD is higher in MPA 
than in GPA (52, 59, 60); in fact, ILD 
has been reported in 23% of GPA pa-
tients (61) and up to 45% of MPA pa-
tients. Anti-MPO antibodies are the 
main ANCA subtype associated to ILD, 
in about 46-71% of cases, while anti-
PR3 antibodies are reported in 0-29% 
of patients (53, 54, 61, 62, 63, 64).
Patients with MPA-ILD show an age 
at onset similar to idiopathic pulmo-
QDU\ÀEURVLV,3)ZKLOH03$SDWLHQWV
without ILD are generally younger (66 
vs. 55 years, for MPA patients with and 
without ILD, respectively). There are 
no conclusive data about gender pre-
dominance, even if some series have re-
ported a slight male predominance (60-
65%) (46, 49, 51, 52, 59, 62, 63, 65-71).
,QFRQWUDVWWRRWKHU$$9OXQJÀEURVLV
is very rare in EGPA, and only one case 
has been described in 2006 (72).
Pathogenesis of interstitial 
lung disease in ANCA-associated 
vasculitis
Several hypotheses have been proposed 
as possible pathogenetic pathways for 
OXQJÀEURVLVLQ$$9
Repeated episodes of intra-alveolar 
haemorrhage have been suggested as a 
possible trigger for an exuberant repar-
ative mechanism (73-75). Although this 
K\SRWKHVLVKDVQRW\HWEHHQFRQÀUPHG
markers of chronic alveolar bleeding 
have been found to be increased in BAL 
ÁXLGDQGKLVWRORJLFVSHFLPHQVRI$$9
ILD subjects (76-77), unlike patients 
with ILD related to other autoimmune 
diseases (75).
Furthermore, MPO-ANCA may play a 
direct role in the pathogenesis of lung 
ÀEURVLV  ZKLOH 35$1&$
seems not to be associated to ILD.
MPO-ANCA may contribute to pul-
monary tissue injury through the pro-
duction of major oxidant products, 
resulting from the activation of MPO 
(80). Furthermore, ANCA-activated 
neutrophils locally release proteloytic 
enzymes, such as elastase (78), or 
neutrophil extracellular traps (NETs), 
produced during a distinct form of cell 
death, named NETosis (81). NETs are 
DEOH WR DFWLYDWH OXQJ ÀEUREODVWV DQG
promote their differentiation into my-
RÀEUREODVWV
Pulmonary damage could also be in-
duced by eosinophils, as proven by 
the report of extensive eosinophilia 
in specimens of ANCA-IPF (83-85). 
0RUHRYHUOXQJÀEUREODVWVPLJKWLQÁX-
Fig. 3. Microscopic 
polyangiitis on HRCT. 
Large patchy area of 
ground glass opacity in 
patient predominantly 
distributed in the right 
lung. HRCT features 
DUH LQGHHG QRW VSHFLÀF
and diagnosis of pul-
monary haemorrhage 
secondary to micro-
scopic polyangiitis can 
be obtained only with 
corroboration from 
FOLQLFRODERUDWRU\ ÀQG-
ings.
Table III. Airway and pulmonary manifes-
tations in microscopic polyangiitis.
Upper airway manifestations %
Sinusitis and nasal mucosa ulcers rare
Lower airway manifestations %
Bronchiectasis 32%
Hypereosinophilic bronchiolitis  55%
Pulmonary manifestations %
Diffuse alveolar haemorrhage 10-55%
8QLRUELODWHUDOSXOPRQDU\LQÀOWUDWHV 
/XQJÀEURVLVLQWHUVWLWLDODEQRUPDOLWLHV 
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ence function and survival of eosino-
phils (84).
On the other side, ILD itself could 
induce MPO-ANCA production, po-
tentially explaining the appearance of 
ANCA after the onset of ILD. Tobacco 
toxicity and chronic lung parenchymal 
ischaemia could be other relevant fac-
tors, stimulating MPO expression in 
epithelial cells (62, 86-88), while pro-
LQÁDPPDWRU\ F\WRNLQHV FRXOG WULJJHU
an autoimmune response against MPO 
normally expressed by activated neu-
trophils (87). In predisposed subjects, 
the consequent production of MPO-
ANCA could lead to AAV.
Finally, a Japanese study has recent-
ly proposed an association between 
usual interstitial pneumonia (UIP) pat-
tern in AAV and the single nucleotide 
polymorphism rs35705950(G/T) in the 
promotor region of MUC5B, encoding 
mucin 5B (89). An association between 
this polymorphism and UIP has been 
already described in IPF (90) and UIP 
related to rheumatoid arthritis (91), 
suggesting a similar pathogenetic path-
way for UIP, independently by the as-
sociated condition.
Clinical manifestations 
of interstitial lung disease in 
ANCA-associated vasculitis
Progressive dyspnoea and non-produc-
tive cough are the main symptoms of 
ILD-related to AAV (63, 65, 92, 93), 
such as in IIPs. 
Other possible manifestations are asso-
FLDWHGZLWKWKHVSHFLÀFW\SHRIYDVFX-
litis, particularly alveolar haemorrhage 
and haemoptysis or constitutional 
symptoms, such as fever and weight 
loss (63, 86, 92).
Vasculitic involvement is common in 
skin (8-31%), peripheral nervous sys-
tem (8-53%), joints and muscles (23-
31%) and kidney (57–100%) in pa-
tients with MPA or GPA (Fig. 5) (51, 
52, 60, 62, 94).
Interestingly, some authors described 
less severe systemic involvement in 
patients with MPA-ILD compared to 
patients without, namely lower erythro-
sedimentation rate, higher haemoglobin 
levels, a lower frequency of diffuse al-
veolar haemorrhage, peripheral nerve 
and kidney involvement (46, 66).
Fig. 4. Surgical lung biopsy in a patient with IPF and p-ANCA positivity, developing a vasculitis with 
features of microscopic polyangiitis. The biopsy shows a classical UIP, consisting in the combination 
RISDWFK\ÀEURVLVDQGÀEUREODVWLFIRFLEDUHO\YLVLEOHDWWKLVPDJQLÀFDWLRQ7KLVVRUWRIKLVWRORJ\LV
identical to UIP in patients with IPF and no clinical features of vasculitis. Haematoxylin-eosin, 40X.
Fig. 5. Surgical lung 
biopsy in a patient with 
the combination of IPF 
and granulomatosis 
with polyangiitis. 
Part of the biopsy shows 
D ÀEURVLQJ ,/' ZLWK
UIP pattern, consisting 
in patchy scarring and 
ÀEUREODVWLFIRFLA). 
)RFDOO\DQLQÁDPPDWR-
ry nodule was present, 
with scattered suppura-
tive foci with palisad-
ing histiocytes (B). 
p-ANCA were positive 
and no microorganisms 
were found.
A: haematoxylin-eosin, 
20x. 
B: haematoxylin-eosin, 
100x.
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Among 33 MPA ANCA-positive pa-
tients, Tzelepis et al. detected ILD in 
12 (36%) at disease onset, while only 
one other developed it later (51, 95). 
All had renal involvement (necrotising, 
segmental glomerulonephritis) and, 
more importantly, patients with ILD 
had a worse prognosis (51, 95).
Imaging of interstitial lung 
disease in ANCA-associated 
vasculitis
HRCT frequently detects interstitial 
lung abnormalities (ILAs) in AAV, in 
particular in MPA patients (96), even if 
the clinical meaning of ILAs occurring 
in asymptomatic patients is nowadays 
GLIÀFXOWWREHHVWDEOLVKHG
In 150 unselected, untreated MPA 
cases, HRCT showed at least one lung 
abnormality in 97% of patients, includ-
ing ILAs in 66% (98). Interestingly, 
similar results have been reported in 
62 MPO-ANCA positive patients with 
or without MPA. Among them, 77% 
showed HRCT abnormalities sugges-
tive for interstitial involvement (99).
**2DUHWKHPRVWIUHTXHQWÀQGLQJVLQ
MPA patients (up to 90% of patients), 
but reticulations, interlobular septal 
thickening and honeycombing are also 
frequently reported (51, 52, 94, 98, 99). 
Moreover, airway abnormalities have 
been reported in 32-55% of cases, main-
ly bronchiolitis, bronchial wall thicken-
ing or bronchiectasis (Fig. 3) (51, 98).
In particular, UIP pattern is described 
in almost half of patients, while non-
VSHFLÀF LQWHUVWLWLDO SQHXPRQLD 16,3
is described in less of a third of cases 
and desquamative interstitial pneumo-
nia in about 15% (46, 51, 52, 59, 60).
In a recent French cohort of AAV and 
ILD, 38/62 patients (61%) showed an 
UIP pattern, while the other 24 (39%) 
a NSIP pattern at HRCT (Fig. 6) (100).
Lung disease is usually symmetrical, 
predominantly involving the lower 
lobes and the peripheral areas of paren-
chyma (52, 59, 94, 99).
&RPELQHGSXOPRQDU\ÀEURVLVZLWKHP-
physema has also been reported in a few 
cases of MPA (60, 98, 101, 102). Finally, 
XSWRRIFDVHVFDQQRWEHFODVVLÀHG
LQ DQ\ VSHFLÀF&7SDWWHUQ   
59, 60), also because of the coexistence 
of different patterns in the same patient.
Prognosis of interstitial lung disease
Many studies comparing MPA patients 
with and without ILD, reported a re-
duced survival for patients with ILD 
(51, 59, 62, 65, 103), with a mortality 2 
to 4 times higher in MPA patients with 
SXOPRQDU\ÀEURVLVFRPSDUHG
to AAV patients without ILD.
Primary causes of death include infec-
tions, progressive respiratory failure, 
and ILD-acute exacerbation (51, 52, 
59, 60, 86). In a study by Fernandez 
Casares et al., respiratory failure was 
the main cause of death in all MPA-
ILD patients (46).
ANCA-positive idiopathic 
interstitial pneumonias
In 1999, Becker-Merok et al. described 
a case of IPF that developed in the fol-
lowing year a segmental pauci-immune 
glomerulonephritis and necrotising 
vasculitis of the peripheral nerves, in-
cluding the presence of p-ANCA anti-
ERGLHVZKLFKDOORZHG WRPDNHDÀQDO
diagnosis of MPA (105). In the next 
years, many other cases have been de-
scribed (51, 52, 59, 62, 63, 65, 86, 93, 
106-108), suggesting the possible as-
sociation among IPF and MPO-ANCA 
with or without clinical manifestations 
for MPA (96). Patients positive for 
MPO-ANCA with idiopathic interstitial 
pneumonia (IIP) include individuals in 
whom ILD precedes MPA (51, 52, 59, 
62, 63, 65, 86, 93, 106-108), but, also 
MPO-ANCA-positive patients that ap-
parently never developed an AAV (64).
ANCA can be frequently found in pa-
tients with IIPs; MPO-ANCA have 
been reported in 4–36% of patients 
with IPF or other IIP, while PR3-AN-
CA are rarer, being found only in 2–4% 
of cases (62-64, 86, 93, 94, 106-108). 
Patients with IPF can develop ANCA 
antibodies in 5–10% of patients nega-
tive at diagnosis (62, 63, 86, 106, 107). 
In various studies including IPF pa-
tients, MPA appeared ranging from 1.7 
to 25.7% of patients during the follow-
up (63, 86, 109).
ILD occurs concurrently or before the 
onset of vasculitis in a large proportion 
of patients. In particular, ILD precedes 
vasculitis in 14–85% of patients, and 
appears simultaneously with other or-
gan involvement in 36–67%. Onset of 
ANCA-associated vasculitis precedes 
the diagnosis of ILD only in 8–21% of 
Fig. 6.3XOPRQDU\ÀEURVLVLQ$1&$DVVRFLDWHGYDVFXOLWV$[LDO&7LPDJHA) shows reticular abnormalities with traction bronchiectasis predominantly 
distributed in the right lower lobe. Both coronal (B) and sagittal (C) reformatted images more clearly depict the traction bronchiectasis and the widespread 
distribution of the reticular abnormalities throughout the lung (courtesy of Valentini A, IRRCS Fondazione Policlinico San Matteo, Pavia, Italy).
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cases (46, 49, 50, 52, 59, 62, 63, 66, 
92, 94, 106, 107, 110-113). The inter-
val between ILD and vasculitis, mainly 
MPA, may be very broad, ranging from 
a few months to 12 years.
In 2018, Hozumi et al. retrospectively 
reviewed 305 consecutive patients ini-
tially diagnosed as IIPs, identifying at 
baseline 16 ANCA-MPO-positive sub-
jects, while other 10 patients developed 
MPO-ANCA in a mean follow-up of 
3.9 years, for an overall prevalence of 
8.5% (114). Among the 26 MPO posi-
tive patients, only 9 developed MPA, 
with a 5-year cumulative incidence for 
MPA of 24.3%. Of interest, MPA was 
more frequent in patients previously di-
agnosed as IPF (6.2%) rather than other 
IIPs (1%) (114). Considering only pa-
tients with an initial diagnosis of IPF, 
11.3% were MPO-ANCA-positive and 
40% of these subsequently developed 
MPA (Fig. 4) (114).
In another retrospective study, 12 pa-
tients with MPO-ANCA/UIP were 
compared with 108 IPF/UIP patients 
(93). Although this study was limited, 
by the low number of patients in MPO-
ANCA/UIP group, the authors observed 
no differences in clinical, laboratory, 
radiological and lung function features 
at baseline, except a higher percentage 
of BAL neutrophils in MPO/UIP group 
(p=0.02). Also, survival and frequency 
of acute exacerbations were the same 
between the 2 groups (93).
In two different North-American co-
horts of IPF, ANCA were positive in 
4% and 5.1% of cases, respectively. The 
2 groups differed for the prevalence of 
35DQWLERGLHV LQ WKHÀUVW WKH\ZHUH
57% (8/14 patients), while PR3 were 
recorded only in 2/20 patients (10%) 
in the other group. The comparison of 
clinical features between ANCA-posi-
tive and negative IPF patients showed 
only a prevalence of female sex in AN-
CA-positive group, but no differences 
in severity of lung disease at enrolment. 
However, compared with ANCA-nega-
tive IPF, ANCA-positive patients were 
VLJQLÀFDQWO\PRUHOLNHO\WRKDYH**2
and moderate/severe honeycombing 
(115).
)LQDOO\SDWLHQWVZLWKSXOPRQDU\ÀEUR-
sis developing MPA had higher ANCA 
titres than those without vasculitis, 
suggesting a predictive value of ANCA 
on the appearance of vasculitis in IPF 
patients (63). 
&RQÁLFWLQJ GDWD KDYH EHHQ UHSRUWHG
DERXW WKHSRVVLEOH LQÁXHQFHRI$1&$
on the survival of IPF patients. In fact, 
many authors described similar surviv-
al rates for patients positive or negative 
for ANCA (53, 62-64, 86, 93, 107). In 
particular, Zhao et al. observed no dif-
ferences in survival rates at 1, 3 and 5 
years between 73 MPA-UIP and 68 IPF 
patients (116). On the other hand, 5- and 
\HDU VXUYLYDOZDV VLJQLÀFDQW ORZHU
in ANCA-positive patients in a large 
cohort of 504 patients with isolated pul-
PRQDU\ÀEURVLV,QWKLVVWXG\WKH
main factors associated with increased 
mortality were PR3-ANCA, age >65 
years and baseline DLCO <70% (105). 
Moreover, a correlation between ANCA 
titre and mortality has been reported by 
various authors (86). Nuzo showed a 
better survival in the low-titre (<50 EU) 
than high-titres (>50 EU) group in AN-
&$SRVLWLYHOXQJÀEURVLV
Finally, an age >65 years at AAV di-
agnosis, an alveolar haemorrhage at 
the time of AAV diagnosis and an UIP 
pattern (compared to NSIP) were inde-
pendent factors associated with shorter 
survival in AAV-ILD patients (100).
Therapeutic approach 
to interstitial lung disease
Currently, only retrospective case se-
ries and a few case reports have been 
published and no controlled clinical tri-
als have been performed for the treat-
ment of ILD in patients with AAV-ILD 
or with IIP and isolated ANCA positiv-
ity (52, 59, 60, 65, 86, 93, 100, 105).
'HVSLWHFRQÁLFWLQJGDWDVWDQGDUGWKHU-
apy for AAV is considered also as a 
possible treatment in patients with ILD 
and includes mainly systemic glucocor-
ticoids, cyclophosphamide, rituximab, 
mycophenolate mofetil, methotrexate 
and azathioprine (5). A study on 49 
AAV-ILD patients suggested a longer 
survival for patients treated with gluco-
corticoids in combination with cyclo-
phosphamide or rituximab compared 
to glucocorticoids alone (60). On the 
other hand, immunosuppressants did 
not improve the prognosis of AAV-ILD 
in a recent study on 62 patients and 
DOVRRWKHUUHSRUWVFRQÀUPHGWKHODFNRI
effectiveness of immunosuppressants 
(52, 59, 65, 100)
In patients with ANCA-positive ILD 
without vasculitis, the therapeutic ap-
proach should not differ by IIP (117), 
although some authors suggest the use 
of immunosuppressive drugs in these 
patients for a supposed autoimmune 
aetiology of the disease. Of interest, 
GHVSLWH VRPH FRQÁLFWLQJ GDWD LPPX-
nosuppressive therapy administered for 
ILD does not seem to reduce the risk of 
subsequent development of AAV (86, 
93, 105). 
Moreover, in patients with an UIP pat-
tern, the histologic and radiologic simi-
larities with IPF (41, 96), as well as some 
common aetiopathogenetic background 
PD\VXJJHVWWKHXVHRIDQWLÀEURWLF
therapies, namely pirfenidone and nin-
tedanib (118). Furthermore, given both 
WKHÀEURWLFDQGLQÁDPPDWRU\DVSHFWVRI
AAV-ILD, a combination of immuno-
VXSSUHVVLYHDQGDQWLÀEURWLFGUXJVPLJKW
be an opportunity for possible future 
therapeutic approaches (118).
A number of trials are currently evaluat-
ing the use of nintedanib and pirfenidone 
LQ SDWLHQWV ZLWK DXWRLPPXQH ÀEURVLQJ
ILD other than IPF (119-124). Among 
them, the open-label study PIRFENI-
VAS is ongoing (NCT03385668) (123) 
with the aims to evaluate the safety and 
the effectiveness of pirfenidone in pa-
tients with MPO-ANCA-positive pul-
PRQDU\ÀEURVLVZLWKRUZLWKRXW$$9
An empiric clinical management ap-
proach, proposed by the Mayo Clinic, 
consists in immunosuppressive thera-
py, according to therapeutic guideline 
for AAV, for patients with systemic 
vasculitis, as well as for patients with 
a NSIP pattern without vasculitis. In 
patients with a UIP pattern, but without 
vasculitis, immunosuppressive therapy 
LVDYRLGHGDQGDQWLÀEURWLFWKHUDS\PD\
be considered (125).
In conclusion, a multidisciplinary ap-
proach including rheumatologist, pul-
monologist, pathologist and radiologist 
and a careful evaluation of progres-
sion and severity of lung involvement, 
should guide the treatment decision; a 
´ZDLW DQG VHHµ DSSURDFK FDQ EH SUR-
posed for non-symptomatic, non-pro-
gressive ILD patients.
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Proposal for patient 
management and treatment
The treatment of AAV-ILD should be 
tailored for each patient and multidis-
ciplinary approach, including at least 
rheumatologist, pulmonologist and 
radiologist, is mandatory to optimise 
therapy and follow-up strategies.
Early diagnosis, functional and radio-
logic follow-up of the lung involve-
ment are necessary to identify patients 
with progressive disease (126, 127). In 
fact, the progression and the severity 
of ILD are the two main factors to be 
considered when a decision-making on 
treatment is requested. Patient’s age, ra-
diologic or histo-pathologic pattern of 
ILD and subjective symptoms should 
also be carefully evaluated (128, 129).
Moreover, when considering therapeu-
tic options for patients with vasculitis, 
both pulmonary and extra-thoracic dis-
ease manifestations need to be assessed 
and taken into account (Fig. 7). Comor-
bidities should be also considered for 
WKHLUSRVVLEOHLQÁXHQFHRQWKHVKRUWDQG
long-term safety of the treatment (dia-
betes mellitus, osteoporosis, etc.) (130).
In such challenging condition, given 
the heterogeneity in disease presenta-
tion, the multiple manifestations that 
may be present, and the broad range of 
disease severity, coordinated care is es-
sential.
In AAV-ILD patients, immunosuppres-
VLYHGUXJVDUHXVXDOO\WKHÀUVWFKRLFH
In particular, cyclophosphamide, my-
cophenolate mofetil, rituximab or aza-
thioprine have been demonstrated ef-
ÀFDF\ RQ$$9DQG KDYH DOVR VKRZHG
some evidence in ILD associated to 
rheumatic diseases (5, 131, 132).
According to the results of INBUILD 
VWXG\ LQ SDWLHQWV ZLWK ÀEURWLF SDWWHUQ
RI ,/' DQG ZLWKRXW VLJQLÀFDQW DFWLY-
ity of vasculitis, it is reasonable to pro-
pose the therapeutic strategies for IPF, 
QDPHO\DQWLÀEURWLFDJHQWVVXFKDVSLUIH-
nidone and nintedanib (117, 119, 133).
,Q SDWLHQWV ZLWK ÀEURWLF SURJUHVVLYH
ILD and active vasculitis, the results of 
INBUILD study and some previous ob-
servations suggest the possibility of a 
combination therapy with both immu-
QRVXSSUHVVDQWVDQGDQWLÀEURWLFDJHQWV
(119, 134-136).
Finally, in asymptomatic patients with 
mild, non-progressive ILD, a “wait and 
VHHµDSSURDFKLVXVXDOO\DGRSWHG
Conclusions
The association between AAV and ILD 
is well-known, but not always investi-
gated in these patients. Moreover, even 
LI,/'VLJQLÀFDQWO\LQÁXHQFHWKHSURJ-
nosis and the quality of life of patients 
with AAV, ILD is not included in any 
activity or severity disease score pro-
posed for AAV (namely BVAS, etc.), 
suggesting the need to review these 
scores in the light of the new knowl-
edge on AAV-ILD (138).
On the other hand, a search for ANCA 
is not usually included in the diagnos-
tic work-up of IIP. Interestingly, ANCA 
have not been included in the research 
criteria for interstitial pneumonia with 
autoimmune features (IPAF), because 
its association with vasculitis rather 
than connective tissue diseases (139), 
and the current criteria do not allow to 
exclude an IPF in ANCA-positive pa-
WLHQWV ZLWK SXOPRQDU\ ÀEURVLV 
For all these reasons, ANCA should be 
investigated in all patients with IIP due to 
WKHSRVVLEOHVLJQLÀFDQWSURJQRVWLFLPSOL-
cations, both on survival and on the risk 
of developing an AAV (46, 49, 51, 52, 59, 
62, 63, 66, 92, 94, 104, 105, 108-111).
Waiting for the results of ongoing tri-
als, the treatment of AAV-ILD remains 
an unmet clinical need. The evaluation 
of the single patient with a multidisci-
plinary approach including rheumatol-
ogist, pulmonologist, pathologist and 
radiologist is mandatory for a correct 
FODVVLÀFDWLRQRIWKHVHSDWLHQWV
Finally, prospective ad hoc study 
should clarify the natural history of 
AAV-ILD and the role of ANCA posi-
tivity in patients with IIP, other than the 
better therapeutic approach for the dif-
ferent groups of patients. 
Fig. 7. Proposed framework for the management and treatment of ANCA-associated vasculits pa-
tients complicated by ILD. Therapeutic choice should derive by a multidisciplinary approach in-
cluding rheumatologist, pulmonologist and radiologist. Use of immunosuppressants or, in selected 
SDWLHQWVDQWLÀEURWLFVKRXOGEHHYDOXDWHGDFFRUGLQJWRWKHDFWLYLW\DQGVHYHULW\RIYDVFXOLWLFPDQLIHV-
tations and ILD.
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